View Older Stories View More Recent Stories

Feb 23, 2017 01:01AM ABLYNX ANNOUNCES 2016 FULL YEAR RESULTS
Feb 16, 2017 01:01AM ABLYNX WILL ANNOUNCE ITS 2016 FULL YEAR RESULTS WITH WEBCAST ON 23 FEBRUARY 2017
Feb 9, 2017 01:01AM ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
Feb 6, 2017 01:01AM ABLYNX SUBMITS A MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR CAPLACIZUMAB, ITS ANTI-vWF NANOBODY, FOR THE TREATMENT OF aTTP
Jan 26, 2017 01:10AM ABLYNX'S PARTNER, MERCK KGaA, REPORTS ENCOURAGING RESULTS WITH THE BI-SPECIFIC NANOBODY ANTI-IL-17A/F (M1095) IN A PHASE Ib CLINICAL STUDY IN PATIENTS WITH PSORIASIS
Jan 24, 2017 01:04AM VAN HERK INVESTMENTS B.V. ANNOUNCES 10.07% SHAREHOLDING IN ABLYNX
Jan 18, 2017 01:06AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jan 11, 2017 11:49AM ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS IN HOSPITALISED INFANTS
Jan 5, 2017 01:19AM ABLYNX TO PRESENT AT THE 35th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Dec 28, 2016 01:06AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Dec 23, 2016 01:07AM FMR LLC ANNOUNCE 9.16% SHAREHOLDING IN ABLYNX
Nov 30, 2016 01:06AM ABLYNX ACHIEVES FIRST MILESTONE AS PART OF COLLABORATION WITH NOVO NORDISK
Nov 23, 2016 01:08AM ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2016 AND A YEAR-TO-DATE BUSINESS UPDATE
Nov 18, 2016 01:05AM FMR LLC ANNOUNCE 9.10% SHAREHOLDING IN ABLYNX
Nov 10, 2016 01:21AM ABLYNX ANNOUNCES WARRANT EXERCISE
Nov 9, 2016 01:15AM ABLYNX TO PRESENT AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE 2016
Oct 21, 2016 01:03AM ABLYNX ANNOUNCES WARRANT EXERCISE
Oct 20, 2016 01:05AM ABLYNX OUTLINES NEXT STEPS FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, A POTENTIAL BEST-IN-CLASS TREATMENT FOR RHEUMATOID ARTHRITIS
Oct 12, 2016 01:04AM ABLYNX ANNOUNCES SECOND EXTENSION OF ITS ION CHANNEL RESEARCH COLLABORATION WITH MERCK & CO., INC.
Oct 11, 2016 01:05AM FMR LLC ANNOUNCE 9.22% SHAREHOLDING IN ABLYNX
Oct 10, 2016 01:15AM ABLYNX INITIATES A PHASE III FOLLOW-UP STUDY OF ITS FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, FOR THE TREATMENT OF ACQUIRED TTP
Sep 29, 2016 01:05AM ABLYNX'S FIRST-IN-CLASS WHOLLY-OWNED ANTI-vWF NANOBODY, CAPLACIZUMAB, MAY HAVE THE POTENTIAL TO REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH ACQUIRED TTP
Sep 15, 2016 01:07AM ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.
Aug 25, 2016 01:10AM ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
Aug 17, 2016 01:09AM ABLYNX WILL ANNOUNCE ITS 2016 HALF YEAR RESULTS WITH WEBCAST ON 25 AUGUST 2016
Aug 12, 2016 01:06AM ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM ADRIANUS VAN HERK ANDVAN HERK INVESTMENTS B.V.
Aug 9, 2016 01:09AM ABLYNX REPORTS COMPELLING TOPLINE PHASE IIb STUDY RESULTS WITH ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, IN RA PATIENTS, CONFIRMING ITS BEST-IN-CLASS POTENTIAL
Aug 4, 2016 01:11AM BANK OF AMERICA CORPORATION ANNOUNCE 5.24% SHAREHOLDING IN ABLYNX
Jul 20, 2016 01:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Jul 7, 2016 01:08AM ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM A PHASE IIb STUDY OF ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB (ALX-0061), AS A MONOTHERAPY IN RA
Jun 16, 2016 12:12PM CORRECTION TRANSPARENCY NOTIFICATION - ADRIANUS VAN HERK ANNOUNCES 3.02% SHAREHOLDING IN ABLYNX
Jun 16, 2016 01:08AM VAN HERK INVESTMENTS ANNOUNCE 3.02% SHAREHOLDING IN ABLYNX
Jun 14, 2016 01:12AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jun 10, 2016 12:07PM PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Jun 3, 2016 01:06AM ABLYNX TO PRESENT AT THE ANNUAL JEFFERIES HEALTHCARE CONFERENCE 2016
May 26, 2016 01:24AM ABLYNX TO PRESENT A POST-HOC ANALYSIS OF THE PHASE II TITAN STUDY WITH CAPLACIZUMAB IN ACQUIRED TTP PATIENTS AT THE 21st CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION
May 13, 2016 01:04AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
May 12, 2016 01:06AM ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2016 AND PROVIDES BUSINESS UPDATE YEAR-TO-DATE
May 3, 2016 01:11AM ABLYNX REPORTS POSITIVE TOP LINE RESULTS FOR ITS INHALED ANTI-RSV NANOBODY (ALX-0171) IN A PHASE I/IIa STUDY IN INFANTS HOSPITALISED WITH AN RSV INFECTION
Apr 29, 2016 01:04AM ABLYNX ANNOUNCES MILESTONE IN DRUG DISCOVERY COLLABORATION
Apr 22, 2016 01:06AM ABLYNX ANNOUNCES WARRANT EXERCISE
Apr 21, 2016 01:05AM ABLYNX TO RECEIVE AN EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS A PHASE I STUDY WITH AN ANTI-CX3CR1 NANOBODY
Mar 22, 2016 02:08AM ABLYNX ANNOUNCES WARRANT EXERCISE
Mar 14, 2016 02:10AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Mar 7, 2016 01:04AM PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
Feb 25, 2016 01:09AM ABLYNX ANNOUNCES 2015 FULL YEAR RESULTS
Feb 23, 2016 01:09AM ABLYNX ANNOUNCES WARRANT EXERCISE
Feb 18, 2016 01:11AM ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016
Feb 11, 2016 01:17AM NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP
Jan 29, 2016 01:06AM ABLYNX TO RECEIVE EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY
View More Recent Stories View Older Stories